A Multicenter, Open-label, Single-arm, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST LTE)

drug protocol number

230LE305

drug sponsor

Biogen Idec Research Limited

drug study

Litifilimab

drug trial site

King Faisal Specialist Hospital and Research Center (Riyadh), King Khalid University Hospital (Riyadh)

drug status

Ongoing

drug phase